Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 4% Improvement Relative Risk Mortality (b) 29% Mortality (c) -65% Ventilation -8% ICU admission -31% Recovery time -29% Hospitalization time -12% Viral clearance 3% Bosaeed et al. HCQ for COVID-19 RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? RCT 254 patients in Saudi Arabia Higher ICU admission (p=0.24) and slower recovery (p=0.29), not stat. sig. Bosaeed et al., Infect. Dis. Ther., doi:10.1007/s40121-021-00496-6 Favors HCQ Favors control
Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
Bosaeed et al., Infect. Dis. Ther., doi:10.1007/s40121-021-00496-6
Bosaeed et al., Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID19 (FACCT.., Infect. Dis. Ther., doi:10.1007/s40121-021-00496-6
Apr 2021   Source   PDF  
  All Studies   Meta
RCT 254 very late stage (93% on oxygen, 17% in ICU at baseline) hospitalized patients in Saudi Arabia not showing significant differences with HCQ+favipiravir treatment. Only SaO2 < 94% patients were eligible, however the actual SaO2 of enrolled patients is not provided. This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline.
risk of death, 3.7% lower, RR 0.96, p = 0.91, treatment 14 of 125 (11.2%), control 15 of 129 (11.6%), NNT 234, 90 days.
risk of death, 28.6% lower, RR 0.71, p = 0.45, treatment 9 of 125 (7.2%), control 13 of 129 (10.1%), NNT 35, 28 days.
risk of death, 65.1% higher, RR 1.65, p = 0.68, treatment 8 of 125 (6.4%), control 5 of 129 (3.9%), 14 days.
risk of mechanical ventilation, 8.4% higher, RR 1.08, p = 0.78, treatment 21 of 125 (16.8%), control 20 of 129 (15.5%).
risk of ICU admission, 31.0% higher, RR 1.31, p = 0.24, treatment 33 of 125 (26.4%), control 26 of 129 (20.2%).
recovery time, 28.6% higher, relative time 1.29, p = 0.29, treatment 125, control 129.
hospitalization time, 12.5% higher, relative time 1.12, p = 0.42, treatment 125, control 129.
risk of no viral clearance, 2.6% lower, RR 0.97, p = 0.75, treatment 100 of 125 (80.0%), control 106 of 129 (82.2%), NNT 46.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bosaeed et al., 30 Apr 2021, Randomized Controlled Trial, Saudi Arabia, peer-reviewed, 30 authors, average treatment delay 5.85 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Infect Dis Ther (2021) 10:2291–2307 ORIGINAL RESEARCH Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial Mohammad Bosaeed . Ebrahim Mahmoud . Ahmad Alharbi . Hadeel Altayib . Hawra Albayat . Faisal Alharbi . Khalid Ghalilah . Abdulmajid Al Arfaj . Jumana AlJishi . Abdullatif Alarfaj . Hajar Alqahtani . Badriah M. Almutairi . Manar Almaghaslah . Nawaf M. Alyahya . Abdullah Bawazir . Saud AlEisa . Abdulrahman Alsaedy . Abderrezak Bouchama . Malak Alharbi . Majid AlShamrani . Sameera Al Johani . Majed Aljeraisy . Mohammed Alzahrani . Abdulhakeem O. Althaqafi . Hassan Almarhabi . Athari Alotaibi . Nasser Alqahtani . Yaseen M. Arabi . Omar S. Aldibasi . Ahmad Alaskar Received: June 3, 2021 / Accepted: July 1, 2021 / Published online: July 28, 2021 Ó The Author(s) 2021 ABSTRACT Introduction: Antiviral drugs have shown limited effectiveness in treating patients with Supplementary Information The online version contains supplementary material available at https:// M. Bosaeed (&)  E. Mahmoud  A. Alharbi  M. Almaghaslah  N. M. Alyahya  A. Bawazir  S. AlEisa  A. Alsaedy Department of Medicine, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia e-mail: M. Bosaeed  E. Mahmoud  A. Alharbi  A. Alsaedy  M. AlShamrani  Y. M. Arabi  A. Alaskar College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia M. Bosaeed  B. M. Almutairi  A. Bouchama  M. AlShamrani  S. Al Johani  M. Aljeraisy  Y. M. Arabi  O. S. Aldibasi  A. Alaskar King Abdullah International Medical Research Center, Riyadh, Saudi Arabia H. Altayib  M. Alzahrani  A. O. Althaqafi  H. Almarhabi Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients. Methods: An investigator-initiated, multicenter, open-label, randomized trial at nine hospitals. Eligible patients were adults with moderate-to-severe COVID-19 defined as H. Albayat Imam Abdulrahman Alfaisal Hospital, Riyadh, Saudi Arabia F. Alharbi Department of Infectious Diseases, King Abdul Aziz Hospital, Makkah, Saudi Arabia K. Ghalilah  M. Alharbi Department of Infectious Diseases, King Salman Medical City, Madinah, Saudi Arabia A. Al Arfaj King Abdulaziz Hospital- Ministry of National Guard Health Affairs, Al Ahsa, Saudi Arabia J. AlJishi Internal Medicine Department, Qatif Central Hospital, Al Qatif, Eastern Province, Saudi Arabia A. Alarfaj Imam Abdulrahman Al Faisal Hospital- Ministry of National Guard Health Affairs, Dammam, Saudi Arabia 2292 Infect Dis Ther (2021) 10:2291–2307 oxygen saturation (SaO2) of B 94% while breathing ambient air or significant clinical symptoms with chest x-ray changes requiring hospital admission. Randomization was in a 1:1 ratio to receive standard care (control group) or standard care plus favipiravir and hydroxychloroquine. The primary outcome was time to clinical improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital within 14 days. Analyses were done in an intention-to-treat population. Results: From May 2020 to Jan..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop